Our association aims to facilitate the transition of the supply chain for the pharma and biotech sector to compliance with net zero emissions in line with the goal of the Paris Climate Agreement.
The alliance has begun development of a roadmap describing what a net zero emission concept for pharmaceutical manufacturing and supply chain would look like and the steps necessary to achieve it. This foundational work also includes agreement on harmonized language and principles for the assessment and control of the total emission footprint for the final pharmaceutical products, as well as the company-specific responsibilities.
We will have raised awareness and created a strong network in the industry. Specific programmes to reduce and offset GHG emissions including waste reduction in pharmaceutical products have been established within our companies. The full supply chain of pharmaceutical products is represented by the Alliance.
Business models have been developed collaboratively based on GHG emissions reduction and Circular Economy principles. We have established transparent key performance indicators for comparing GHG emissions reduction across the industry. We have developed a net zero product offering within the Alliance.
Our company operations covering the supply chain of the net zero product offering will be net zero or show significant GHG emissions reduction. We will have enabled the launch of net zero pharmaceutical products in regulated markets. As per a third-party audit, the overall supply chain is confirmed net zero.